药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Mecasermin
Tregalizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tregalizumab.
Mecasermin
Racotumomab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Racotumomab.
Mecasermin
Namilumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Namilumab.
Mecasermin
Rovalpituzumab Tesirine
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Rovalpituzumab Tesirine.
Mecasermin
Robatumumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Robatumumab.
Mecasermin
Milatuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Milatuzumab.
Mecasermin
Bimekizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bimekizumab.
Mecasermin
Sacituzumab govitecan
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sacituzumab govitecan.
Mecasermin
Ozanezumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ozanezumab.
Mecasermin
Clazakizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Clazakizumab.
Mecasermin
Amatuximab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Amatuximab.
Mecasermin
Rontalizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Rontalizumab.
Mecasermin
Depatuxizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Depatuxizumab.
Mecasermin
Concizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Concizumab.
Mecasermin
Crotedumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Crotedumab.
Mecasermin
Naptumomab Estafenatox
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Naptumomab Estafenatox.
Mecasermin
Ecromeximab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ecromeximab.
Mecasermin
Abituzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Abituzumab.
Mecasermin
Sifalimumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sifalimumab.
Mecasermin
Demcizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Demcizumab.